Clinical trialsCompany release

PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer

🇺🇸 PMV Pharmaceuticals, Inc. (PMVP) · Fri 20 Nov 2026

Updated pivotal PYNNACLE data in TP53 Y220C-mutated tumours support a planned accelerated approval filing for platinum-resistant or refractory ovarian cancer in the first quarter of 2027.

PMV Pharmaceuticals presented updated results from the pivotal Phase 2 PYNNACLE trial on 20 November 2026 at ENA 2026 in Barcelona. The study tests rezatapopt as monotherapy in advanced solid tumours carrying the TP53 Y220C mutation.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): PMV Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (PMV Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.